News

The FDA has assigned a target action date of February 28, 2026, for a potential expanded indication of pegvaliase-pqpz to include adolescents with PKU.

Can you diagnose this 10-year-old with an oozy ear?

A pair of phase 3 trials showed that AbbVie's daily upadacitinib 15 mg led to a 50% reduction in T-VASI 50 and a 75% reduction in F-VASI 75 at 48 weeks among adolescents 12 years and older.

In this Q&A, nurse practitioner Tracey Gaslin, PhD, discusses tick bites in pediatric patients, from how to prevent a bite to what to do after a bite, and highlights resources available from the Fight the Bite initiative.

Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, shares her thoughts on a featured article from the October 2025 issue of Contemporary Pediatrics.

Key highlights from the conference included public health, advocacy for vaccines, and artificial intelligence.

He had no prior history of recurrent ear infections, abscesses, or boils. Can you guess the diagnosis?

Zoliflodacin study investigator Sarah McLeod, PhD, highlights data presented at IDWeek 2025 in this Q&A with Contemporary Pediatrics.

New one-year data showed that baricitinib continued scalp, eyebrow, and eyelash regrowth in adolescents with severe alopecia areata.

The FDA acknowledged that the primary endpoint was met but that "data do not support the effectiveness of low-dose atropine in children with myopia," according to Sydnexis.

A single injection once per 8 weeks vs once per 4 weeks demonstrated similar levles of skin clearance, for AD patients 12 years and older, according to a Fall Clinical announcement.

New patient- and caregiver-reported outcomes across 3 phase 3 trials demonstrated improved itch and reduced impact of AD on sleep in patients 2 years and older.

Updated 2025 CPR guidelines from the AAP and AHA include revisions to pediatric and neonatal resuscitation, reflecting new evidence and a unified chain of survival.

In this Q&A, Abby Nerlinger, MD, breaks down how pediatricians can provide detailed care for children with military connections, based on a session presented at the 2025 AAP National Conference & Exhibition.

In this brief clip, Lori Handy, MD, MSCE, of CHOP, explains the evolving dynamic of trust between patients, parents, and health care.

Lori Handy, MD, MSCE, discussed how clinicians can strengthen vaccine communication by engaging openly and partnering with trusted community messengers.

Nicholas P. Marshall, MD, FAAP, discussed how generative AI can help streamline infectious disease workflows and enhance evidence-based care at IDWeek 2025 in Atlanta.

Yohei Doi, MD, IDWeek chair, Infectious Diseases Society of America, provides some insights on the happenings at this year’s event from Atlanta, Georgia.

Children born preterm face significantly reduced odds of completing high school and university compared with full-term peers.

* Generic lenacapavir could be produced for $25 per person per year at scale, according to an analysis presented at IDWeek 2025 in Atlanta.

Unintentional marijuana ingestions in children under 5 rose over 1,000% in 7 years, with edibles and pandemic-related factors fueling the trend.

Combined or individual use of maternal RSVpreF and infant nirsevimab achieved high antibody levels without safety concerns, supporting current RSV prevention strategies.

A study of 3,438 toddlers found slightly lower emotional and behavioral problems among children assessed during the COVID-19 pandemic.

Tezepelumab received FDA approval for CRSwNP in patients 12 years and older, supported by strong phase 3 data.

At CNS 2025, Kathryn Xixis, MD, highlighted the growing adoption of EPAs and outcomes-based learning in pediatric neurology.

Indication expansions include hidradenitis suppurativa for patients 12 years and up, as well as for patients with uveitis aged 2 years and older.

In our second interview with Peace Madueme, MD, he explains the types of conditions that frequently appear on ECGs, which are aiding routine sports physicals in youth athletes in Florida.

A pediatrician warns of the resurgence of vaccine-preventable diseases, urging awareness of their devastating impacts on children's health.

IDWeek 2025 heads to Atlanta October 19–22 with cutting-edge sessions on AMR, AI, vaccines, HIV, pediatrics, and global health challenges.